SRC激酶驱动由KRAS-G12C抑制诱导的多药耐药性
Xinxin Song1, Zhuan Zhou1, Ammar Elmezayen2
1Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Science advances
|December 11, 2024
概括
克拉斯-G12C抑制剂在癌症中面临抗药性. 将SRC抑制剂与这些药物结合起来,通过向JUN-ABCC1通路来克服耐药性,从而提高治疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- KRAS-G12C突变驱动非小细胞肺癌 (NSCLC) 和胰腺癌.
- 向KRAS-G12C的共价抑制剂 (G12Ci) 是有前途的,但面临着新兴的耐药性.
- 了解耐药机制对于提高G12Ci疗效至关重要.
研究的目的:
- 研究在KRAS-G12C突变癌症中MRTX849耐药性的机制.
- 确定克服MRTX849耐药性的治疗策略.
- 评估SRC抑制剂与G12Ci的协同效应.
主要方法:
- 全基因组的CRISPR屏幕用于识别抗性介质.
- 关于基因表达和耐药性的功能研究.
- 无偏见的药物查和临床前验证在小鼠模型和有机体.
主要成果:
- 通过CRISPR屏幕,ABCC1被确定为MRTX849抗性的调解者.
- JUN转录因子驱动ABCC1表达,导致多药性耐药性.
- 达沙替尼是一种SRC抑制剂,通过抑制SRC依赖的JUN激活来增强MRTX849的疗效.
- 在KRAS-G12C突变癌症模型中,SRC抑制剂与MRTX849具有协同作用.
结论:
- SRC 抑制剂可以通过向 JUN-ABCC1 途径来克服 G12Ci 抵抗.
- 将SRC抑制剂与G12Ci结合起来,可以提高KRAS-G12C突变癌症的治疗效果.
- SRC 抑制剂扩大了G12Ci在治疗NSCLC和胰腺癌方面的治疗潜力.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


